Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.37 |
| ▸ | RELA | Q04206 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992927 | 0.87 | NFKB1 (0.42) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL29046634 | 0.86 | BTK (0.47) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL9114182 | 0.86 | BTK (0.47) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL9114187 | 0.86 | BTK (0.47) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL9114179 | 0.86 | BTK (0.47) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL25070921 | 0.83 | BTK (0.40) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL22475417 | 0.81 | NFKB1 (0.39) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL12631404 | 0.80 | BTK (0.45) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL22541541 | 0.80 | MAPK1 (0.36) | MEN1MAPK1KMT2A | |
| SCHEMBL31081654 | 0.80 | GAA (0.35) | NFKB1NFKB2RELAKDM1ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4522622-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | NFKB1 2896/4885NFKB2 2125/4885RELA 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.